Fig. 2.

The HRD-DNA model predicts HRD status from gwLOH. A Thresholds for calling a sample HRD+ for breast and ovarian cancer were set based on the maximum F1-score within samples in the training set. B Metrics used to assess HRD-DNA performance within the evaluation set. The confidence interval for breast cancer was [1, 1] and ovarian cancer AUC was [0.979, 1]. C Distribution of gwLOH scores across different HRR genotypes in the evaluation set. HRR mutated samples contain samples with either monoallelic or biallelic loss in a select number of HRR genes. Values in the box represent the median gwLOH percentage within each HRR genotype (**** p-value < 0.0001 for Wilcoxon test). Dotted lines are the thresholds chosen in (A) for each cancer type. Statistical differences between HRR-WT and BRCA biallelic loss were not shown, but all were significant (p-value < 0.0001 for Wilcoxon test)